Rheumatoid Arthritis — Common Origins, Divergent Mechanisms | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Importance Rheumatoid arthritis (RA) occurs in about 5 per 1000 people and can lead to
severe joint damage and disability. Significant progress has been made over the past 2 …

Background Despite treatment according to the current management recommendations, a
significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These …

Objective To develop evidence-based European Alliance of Associations for Rheumatology
(EULAR) points to consider (PtCs) for the management of difficult-to-treat rheumatoid …

Rheumatoid arthritis is a common chronic inflammatory disorder and a major cause of
disability. Despite the progress made with recent clinical use of anti-cytokine biologics, the …

Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease,
affecting the joints with varying severity among patients. The risk factors include age …

Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …

Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …

Objective To update the European League Against Rheumatism (EULAR) recommendations
for the pharmacological treatment of psoriatic arthritis (PsA). Methods According to the …

Methotrexate (MTX) is used as an anchor disease-modifying anti-rheumatic drugs
(DMARDs) in treating rheumatoid arthritis (RA) because of its potent efficacy and tolerability …